Skip to content
The Nexus
BUSINESSJun 24 · 11:00 UTCSTAT NEWSAllison DeAngelis

STAT+: Ophthalmology venture grabs investors’ attention, raises $330 million

Ollin Biosciences, a startup developing treatments for eye diseases, raised $330 million in a Series B funding round led by TCGX and ARCH Venture Partners. The company is preparing for a Phase 3 trial of a treatment targeting diabetic macular edema and wet age-related macular degeneration.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
Ollin BiosciencesorganizationTCGXorganizationARCH Venture Partnersorganizationdiabetic macular edematopicwet age-related macular degenerationtopic
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting